By Christian Moess Laursen

 

AstraZeneca said Tuesday that its Farxiga treatment has been approved in the U.S for use on patients with heart failure.

The Anglo-Swedish pharma giant said Farxiga was previously approved in the U.S. for adults with heart failure with reduced ejection fraction.

The approval by the Food and Drug Administration was based on positive results from a trial evaluating the efficacy of Farxiga, the company said.

 

Write to Christian Moess Laursen at christian.moess@wsj.com

 

(END) Dow Jones Newswires

May 09, 2023 02:31 ET (06:31 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.
AstraZeneca (NASDAQ:AZN)
Gráfico Histórico do Ativo
De Fev 2024 até Mar 2024 Click aqui para mais gráficos AstraZeneca.
AstraZeneca (NASDAQ:AZN)
Gráfico Histórico do Ativo
De Mar 2023 até Mar 2024 Click aqui para mais gráficos AstraZeneca.